Home Alzheimer’s Disease FDA Grants Priority Review to Sodium Thiosulfate for Ototoxicity Prevention

FDA Grants Priority Review to Sodium Thiosulfate for Ototoxicity Prevention

The FDA has granted priority review to the new drug application (NDA) for sodium thiosulfate (Pedmark) for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to <18 years of age with localized, non-metastatic, solid tumors, according to Fennec Pharmaceuticals, the drug’s developer.1

A prescription drug user fee act (PDUFA) target action date of August 10, 2020 was set by the FDA for the completion of the review.

“The FDA filing acceptance of our NDA and granting of priority review represents a significant milestone in the development of Pedmark and we look forward to working closely with the Agency during this review process,” Rosty Raykov, chief executive officer of Fennec, said in a press release. 

Sodium thiosulfate has been studied by cooperative groups in 2 phase III clinical studies of survival and reduction of ototoxicity, The Clinical…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Cause of Alzheimer’s disease traced to mutation in common enzyme

submitted by /u/scotsman81 Continue Reading to the Source

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

Recent Comments